http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2726602-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_347b2fb4c8b2bbac962ec15125fd4459 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-02 |
| filingDate | 2019-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9168b9d3aa084cb7c337d2c2ed3410eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27ec5092dfb350b27a986bbe11a527ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a095bdd43887bf172aa298c4d781acff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2dee4cc2b8bc1e659d6c7528d10bf21 |
| publicationDate | 2020-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2726602-C1 |
| titleOfInvention | Method of controlling clinical effectiveness of drug-intensive therapy |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to intensive care. HRV parameters are recorded by 5-minute recording of RR intervals of the electrocardiogram initially, and on 1 st , 5 th , 10 th and 15 th day of using the drug in the course of drug-intensive therapy. Condition of sympathetic hyperactivity of the autonomous nervous system (ANS) is diagnosed within the limits of values: SDNN less than 13.31 ms; RMSSD is less than 5.78 ms, pNN50 % is less than 0.110 %, SI is more than 900 nu, TP is less than 200 ms 2 . ANS norm state is determined within the values: SDNN from 13.31 to 41.4 ms, RMSSD from 5.78 to 42.3 ms, pNN50% from 0.110 to 8.1%, SI from 80 to 900 nu, TP from 200 to 2000 ms 2 . Or, the condition of parasympathetic hyperactivity is determined within the following limits: SDNN is more than 41.4 ms, RMSSD is more than 42.3 ms, pNN50 % is more than 8.1 %, SI is less than 80 nu, TP is more than 2000 ms 2 . Administration of a pharmacological preparation which reduces the activity of the sympathetic link of ANS is prescribed in the presence of at least 3 of any HRV parameters corresponding to the range of sympathetic hyperactivity of ANS. That is followed by the introduction of a pharmacological preparation which lowers the activity of the sympathetic link of ANS, with the possibility of correcting the introduction mode - the rate and dose of administration depending on the HRV values, until the HRV values corresponding to the ANS functional state norm are achieved. If observing the HRV values corresponding to the functional status of the ANS, the use of the pharmacological preparation is continued until the end of the IC course. If the patient has at least 3 any parameters corresponding to the parasympathetic hyperactivity state, the use of the pharmacological preparation reducing the ANS sympathetic link activity is terminated or the introduction mode is corrected. Administration of a pharmacological preparation increasing activity of the ANS sympathetic link is prescribed in the presence of at least 3 any HRV parameters corresponding to the ANS parasympathetic hyperactivity state range, with the possibility of adjusting the introduction mode - the rate and dose of the introduction depending on the HRV values until the functional condition of the ANS is achieved. If observing the HRV values corresponding to the functional status of the ANS, the use of the pharmacological preparation is continued until the end of the IC course. If any at least 3 any indicators corresponding to the state of sympathetic hyperactivity appear in the patient, use of a pharmacological preparation increasing activity of the ANS sympathetic link stops or corrects a mode of administration. n EFFECT: method enables monitoring the patient's state and the course of the intensive drug therapy on the bedside microprocessor devices, by determining a range of normal and abnormal HRV, reflecting the functional state of ANS; exclude overdose of used pharmacological agent to developing clinically significant adverse effects by detecting reaction of ANS and body as a whole to conducted treatment. n 1 cl, 6 ex |
| priorityDate | 2019-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.